Skip to main content
. 2011 Jun 9;34(7):454–460. doi: 10.1002/clc.20908

Table 1.

Clinical Characteristics of Studied Patients

Group A Group B Group C Group D P
No. 40 34 42 15
Age, y 70.4 ± 8.1 67.4 ± 10.6 70.1 ± 9.9 74.5 ± 8.6 0.1222
Sex (male) 25 (62.5%) 23 (67.6%) 27 (64.3%) 11 (73.3%) 0.8818
Risk factor
HT 24 (60.0%) 25 (73.5%) 32 (76.2%) 14 (93.3%) 0.0586
HL 32 (80.0%) 26 (76.5%) 17 (40.5%) 7 (46.7%) 0.0003
DM 16 (40.0%) 15 (44.1%) 11 (26.2%) 5 (33.3%) 0.3752
Laboratory data
TG 171.0 ± 121.8 175.0 ± 141.5 151.9 ± 73.0 143.4 ± 78.1 0.7044
HDL‐C 49.9 ± 13.8 47.4 ± 12.7 48.9 ± 11.6 51.3 ± 12.8 0.7713
LDL‐C 112.9 ± 33.1 132.2 ± 41.1 107.0 ± 27.6 121.4 ± 24.8 0.1593
TC 189.5 ± 39.0 196.6 ± 39.4 182.5 ± 21.6 189.8 ± 22.8 0.4948
BS 121.2 ± 33.8 143.8 ± 52.9 125.4 ± 41.1 132.9 ± 37.8 0.1427
HbA1c 6.2 ± 1.5 6.1 ± 1.2 5.7 ± 0.9 5.8 ± 1.0 0.3767
Medication
Aspirin 35 (87.5%) 31 (91.2%) 19 (45.2%) 3 (20.0%) <0.0001
Statin 25 (62.5%) 19 (55.9%) 12 (28.6%) 2 (13.3%) 0.0008
ACEI/ARB 10 (25.0%) 18 (52.9%) 15 (35.7%) 10 (66.7%) 0.0082
CCB 13 (32.5%) 12 (35.3%) 14 (33.3%) 7 (46.7%) 0.7323
BB 11 (27.5%) 8 (23.5%) 7 (16.7%) 1 (6.7%) 0.3711
Lesion location
LAD 22 (55.0%) 22 (64.7%) 22 (52.4%) 10 (66.7%)
RCA 11 (27.5%) 8 (23.5%) 14 (33.3%) 4 (26.7%)
LCX 7 (17.5%) 4 (11.8%) 6 (14.3%) 1 (6.7%) 0.8701

Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β‐blocker; BS, blood sugar; CCB, calcium channel blocker; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; HL, hyperlipidemia; HT, hypertension; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LDL‐C, low‐density lipoprotein cholesterol; RCA, right coronary artery; TC, total cholesterol; TG; triglyceride.